The Experts below are selected from a list of 12090 Experts worldwide ranked by ideXlab platform
Michael M Mcchesney - One of the best experts on this subject based on the ideXlab platform.
-
Maternal Antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth
Virology, 2006Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Azaibi Tamin, Gregory Hodge, Michael M McchesneyAbstract:Maternal Antibody prevents the use of live, attenuated measles vaccine (LAV) before 6–9 months of age, but vaccinated 6-month-old infants can mount a T cell response. An infant macaque model was used to study the immune response to LAV in the newborn in the presence or absence of Maternal Antibody. Four newborn monkeys without detectable Maternal Antibody and 9 newborns with passive measles Antibody were vaccinated with LAV. Only the infants without passive Antibody seroconverted after vaccination and 3 of 4 of these infants also developed measles-specific interferon γ+ T cells. The monkeys were challenged with wild-type measles virus at 5 months of age, and 7 of 9 infants vaccinated in the presence of passive Antibody had systemic infection and skin rash, while 3 of the 4 infants vaccinated in the absence of passive Antibody were protected from viremia and rash. This suggests that the newborn can respond to LAV but that Maternal Antibody suppresses the priming of both humoral and cellular immunity at birth.
-
protection against challenge with measles virus mv in infant macaques by an mv dna vaccine administered in the presence of neutralizing Antibody
The Journal of Infectious Diseases, 2004Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Gary Rhodes, Michael M McchesneyAbstract:Measles virus (MV) infection is the major cause of vaccine-preventable death in infants and children worldwide. It is difficult to achieve immunity to MV infection by use of vaccines in infants during the first 6-9 months of life because of the presence of Maternal Antibody. Morbidity and mortality due to MV infection would decrease substantially if a vaccine administered at birth could prime immunity in the presence of Maternal Antibody. We demonstrate here that an MV DNA vaccine administered to infant macaques in the presence of Maternal Antibody primes MV-specific T cell responses but not de novo neutralizing Antibody. This vaccine protected 80% of the infant macaques from skin rash and MV-induced immunosuppression. A molecular interleukin-2 adjuvant was required for protection with this vaccine. This macaque model shows that infants can be vaccinated against MV in the presence of Maternal Antibody. These results suggest that it is possible to develop an MV DNA vaccine that could protect infants in developing countries during the first months of life.
-
dna vaccination of infants in the presence of Maternal Antibody a measles model in the primate
Virology, 2003Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Nicholas W Lerche, Gary Rhodes, David Verhoeven, Dan H Barouch, Norman L Letvin, Michael M McchesneyAbstract:To eradicate measles in developing nations a vaccine capable of being administered at birth may be necessary. We immunized newborn rhesus macaques with naked DNA encoding the measles virus hemagglutinin, fusion and nucleoprotein genes. Prior to vaccination we passively transferred measles immunoglobulin to mimic Maternal Antibody. In the presence or absence of measles immunoglobulin, 23 of 25 infant macaques had detectable cell mediated immunity and 16 had protective levels of neutralizing Antibody. The co-administration of an IL-2/IgG plasmid augmented the vaccine, increasing cell mediated immunity in all infants and increasing the Antibody response in infants vaccinated without immunoglobulin. We show for the first time that DNA vaccination can protect a newborn primate from the high-level viremia that correlates with severe measles, even in the presence of Maternal Antibody. Further, the addition of a molecular IL-2 adjuvant augments this DNA vaccine.
-
evaluation of recombinant vaccinia virus measles vaccines in infant rhesus macaques with preexisting measles Antibody
Virology, 2000Co-Authors: Yongde Zhu, William J. Bellini, Paul A Rota, Linda S Wyatt, Azaibi Tamin, Shmuel Rozenblatt, Nicholas W Lerche, Bernard Moss, Michael M McchesneyAbstract:Immunization of newborn infants with standard measles vaccines is not effective because of the presence of Maternal Antibody. In this study, newborn rhesus macaques were immunized with recombinant vaccinia viruses expressing measles virus hemagglutinin (H) and fusion (F) proteins, using the replication-competent WR strain of vaccinia virus or the replication-defective MVA strain. The infants were boosted at 2 months and then challenged intranasally with measles virus at 5 months of age. Some of the newborn monkeys received measles immune globulin (MIG) prior to the first immunization, and these infants were compared to additional infants that had Maternal measles-neutralizing Antibody. In the absence of measles Antibody, vaccination with either vector induced neutralizing Antibody, cytotoxic T cell (CTL) responses to measles virus and protection from systemic measles infection and skin rash. The infants vaccinated with the MVA vector developed lower measles-neutralizing Antibody titers than those vaccinated with the WR vector, and they sustained a transient measles viremia upon challenge. Either Maternal Antibody or passively transferred MIG blocked the humoral response to vaccination with both WR and MVA, and the frequency of positive CTL responses was reduced. Despite this inhibition of vaccine-induced immunity, there was a reduction in peak viral loads and skin rash after measles virus challenge in many of the infants with preexisting measles Antibody. Therefore, vaccination using recombinant vectors such as poxviruses may be able to prevent the severe disease that often accompanies measles in infants.
William J. Bellini - One of the best experts on this subject based on the ideXlab platform.
-
Maternal Antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth
Virology, 2006Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Azaibi Tamin, Gregory Hodge, Michael M McchesneyAbstract:Maternal Antibody prevents the use of live, attenuated measles vaccine (LAV) before 6–9 months of age, but vaccinated 6-month-old infants can mount a T cell response. An infant macaque model was used to study the immune response to LAV in the newborn in the presence or absence of Maternal Antibody. Four newborn monkeys without detectable Maternal Antibody and 9 newborns with passive measles Antibody were vaccinated with LAV. Only the infants without passive Antibody seroconverted after vaccination and 3 of 4 of these infants also developed measles-specific interferon γ+ T cells. The monkeys were challenged with wild-type measles virus at 5 months of age, and 7 of 9 infants vaccinated in the presence of passive Antibody had systemic infection and skin rash, while 3 of the 4 infants vaccinated in the absence of passive Antibody were protected from viremia and rash. This suggests that the newborn can respond to LAV but that Maternal Antibody suppresses the priming of both humoral and cellular immunity at birth.
-
protection against challenge with measles virus mv in infant macaques by an mv dna vaccine administered in the presence of neutralizing Antibody
The Journal of Infectious Diseases, 2004Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Gary Rhodes, Michael M McchesneyAbstract:Measles virus (MV) infection is the major cause of vaccine-preventable death in infants and children worldwide. It is difficult to achieve immunity to MV infection by use of vaccines in infants during the first 6-9 months of life because of the presence of Maternal Antibody. Morbidity and mortality due to MV infection would decrease substantially if a vaccine administered at birth could prime immunity in the presence of Maternal Antibody. We demonstrate here that an MV DNA vaccine administered to infant macaques in the presence of Maternal Antibody primes MV-specific T cell responses but not de novo neutralizing Antibody. This vaccine protected 80% of the infant macaques from skin rash and MV-induced immunosuppression. A molecular interleukin-2 adjuvant was required for protection with this vaccine. This macaque model shows that infants can be vaccinated against MV in the presence of Maternal Antibody. These results suggest that it is possible to develop an MV DNA vaccine that could protect infants in developing countries during the first months of life.
-
dna vaccination of infants in the presence of Maternal Antibody a measles model in the primate
Virology, 2003Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Nicholas W Lerche, Gary Rhodes, David Verhoeven, Dan H Barouch, Norman L Letvin, Michael M McchesneyAbstract:To eradicate measles in developing nations a vaccine capable of being administered at birth may be necessary. We immunized newborn rhesus macaques with naked DNA encoding the measles virus hemagglutinin, fusion and nucleoprotein genes. Prior to vaccination we passively transferred measles immunoglobulin to mimic Maternal Antibody. In the presence or absence of measles immunoglobulin, 23 of 25 infant macaques had detectable cell mediated immunity and 16 had protective levels of neutralizing Antibody. The co-administration of an IL-2/IgG plasmid augmented the vaccine, increasing cell mediated immunity in all infants and increasing the Antibody response in infants vaccinated without immunoglobulin. We show for the first time that DNA vaccination can protect a newborn primate from the high-level viremia that correlates with severe measles, even in the presence of Maternal Antibody. Further, the addition of a molecular IL-2 adjuvant augments this DNA vaccine.
-
evaluation of recombinant vaccinia virus measles vaccines in infant rhesus macaques with preexisting measles Antibody
Virology, 2000Co-Authors: Yongde Zhu, William J. Bellini, Paul A Rota, Linda S Wyatt, Azaibi Tamin, Shmuel Rozenblatt, Nicholas W Lerche, Bernard Moss, Michael M McchesneyAbstract:Immunization of newborn infants with standard measles vaccines is not effective because of the presence of Maternal Antibody. In this study, newborn rhesus macaques were immunized with recombinant vaccinia viruses expressing measles virus hemagglutinin (H) and fusion (F) proteins, using the replication-competent WR strain of vaccinia virus or the replication-defective MVA strain. The infants were boosted at 2 months and then challenged intranasally with measles virus at 5 months of age. Some of the newborn monkeys received measles immune globulin (MIG) prior to the first immunization, and these infants were compared to additional infants that had Maternal measles-neutralizing Antibody. In the absence of measles Antibody, vaccination with either vector induced neutralizing Antibody, cytotoxic T cell (CTL) responses to measles virus and protection from systemic measles infection and skin rash. The infants vaccinated with the MVA vector developed lower measles-neutralizing Antibody titers than those vaccinated with the WR vector, and they sustained a transient measles viremia upon challenge. Either Maternal Antibody or passively transferred MIG blocked the humoral response to vaccination with both WR and MVA, and the frequency of positive CTL responses was reduced. Despite this inhibition of vaccine-induced immunity, there was a reduction in peak viral loads and skin rash after measles virus challenge in many of the infants with preexisting measles Antibody. Therefore, vaccination using recombinant vectors such as poxviruses may be able to prevent the severe disease that often accompanies measles in infants.
Paul A Rota - One of the best experts on this subject based on the ideXlab platform.
-
Maternal Antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth
Virology, 2006Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Azaibi Tamin, Gregory Hodge, Michael M McchesneyAbstract:Maternal Antibody prevents the use of live, attenuated measles vaccine (LAV) before 6–9 months of age, but vaccinated 6-month-old infants can mount a T cell response. An infant macaque model was used to study the immune response to LAV in the newborn in the presence or absence of Maternal Antibody. Four newborn monkeys without detectable Maternal Antibody and 9 newborns with passive measles Antibody were vaccinated with LAV. Only the infants without passive Antibody seroconverted after vaccination and 3 of 4 of these infants also developed measles-specific interferon γ+ T cells. The monkeys were challenged with wild-type measles virus at 5 months of age, and 7 of 9 infants vaccinated in the presence of passive Antibody had systemic infection and skin rash, while 3 of the 4 infants vaccinated in the absence of passive Antibody were protected from viremia and rash. This suggests that the newborn can respond to LAV but that Maternal Antibody suppresses the priming of both humoral and cellular immunity at birth.
-
protection against challenge with measles virus mv in infant macaques by an mv dna vaccine administered in the presence of neutralizing Antibody
The Journal of Infectious Diseases, 2004Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Gary Rhodes, Michael M McchesneyAbstract:Measles virus (MV) infection is the major cause of vaccine-preventable death in infants and children worldwide. It is difficult to achieve immunity to MV infection by use of vaccines in infants during the first 6-9 months of life because of the presence of Maternal Antibody. Morbidity and mortality due to MV infection would decrease substantially if a vaccine administered at birth could prime immunity in the presence of Maternal Antibody. We demonstrate here that an MV DNA vaccine administered to infant macaques in the presence of Maternal Antibody primes MV-specific T cell responses but not de novo neutralizing Antibody. This vaccine protected 80% of the infant macaques from skin rash and MV-induced immunosuppression. A molecular interleukin-2 adjuvant was required for protection with this vaccine. This macaque model shows that infants can be vaccinated against MV in the presence of Maternal Antibody. These results suggest that it is possible to develop an MV DNA vaccine that could protect infants in developing countries during the first months of life.
-
dna vaccination of infants in the presence of Maternal Antibody a measles model in the primate
Virology, 2003Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Nicholas W Lerche, Gary Rhodes, David Verhoeven, Dan H Barouch, Norman L Letvin, Michael M McchesneyAbstract:To eradicate measles in developing nations a vaccine capable of being administered at birth may be necessary. We immunized newborn rhesus macaques with naked DNA encoding the measles virus hemagglutinin, fusion and nucleoprotein genes. Prior to vaccination we passively transferred measles immunoglobulin to mimic Maternal Antibody. In the presence or absence of measles immunoglobulin, 23 of 25 infant macaques had detectable cell mediated immunity and 16 had protective levels of neutralizing Antibody. The co-administration of an IL-2/IgG plasmid augmented the vaccine, increasing cell mediated immunity in all infants and increasing the Antibody response in infants vaccinated without immunoglobulin. We show for the first time that DNA vaccination can protect a newborn primate from the high-level viremia that correlates with severe measles, even in the presence of Maternal Antibody. Further, the addition of a molecular IL-2 adjuvant augments this DNA vaccine.
-
evaluation of recombinant vaccinia virus measles vaccines in infant rhesus macaques with preexisting measles Antibody
Virology, 2000Co-Authors: Yongde Zhu, William J. Bellini, Paul A Rota, Linda S Wyatt, Azaibi Tamin, Shmuel Rozenblatt, Nicholas W Lerche, Bernard Moss, Michael M McchesneyAbstract:Immunization of newborn infants with standard measles vaccines is not effective because of the presence of Maternal Antibody. In this study, newborn rhesus macaques were immunized with recombinant vaccinia viruses expressing measles virus hemagglutinin (H) and fusion (F) proteins, using the replication-competent WR strain of vaccinia virus or the replication-defective MVA strain. The infants were boosted at 2 months and then challenged intranasally with measles virus at 5 months of age. Some of the newborn monkeys received measles immune globulin (MIG) prior to the first immunization, and these infants were compared to additional infants that had Maternal measles-neutralizing Antibody. In the absence of measles Antibody, vaccination with either vector induced neutralizing Antibody, cytotoxic T cell (CTL) responses to measles virus and protection from systemic measles infection and skin rash. The infants vaccinated with the MVA vector developed lower measles-neutralizing Antibody titers than those vaccinated with the WR vector, and they sustained a transient measles viremia upon challenge. Either Maternal Antibody or passively transferred MIG blocked the humoral response to vaccination with both WR and MVA, and the frequency of positive CTL responses was reduced. Despite this inhibition of vaccine-induced immunity, there was a reduction in peak viral loads and skin rash after measles virus challenge in many of the infants with preexisting measles Antibody. Therefore, vaccination using recombinant vectors such as poxviruses may be able to prevent the severe disease that often accompanies measles in infants.
Azaibi Tamin - One of the best experts on this subject based on the ideXlab platform.
-
Maternal Antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth
Virology, 2006Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Azaibi Tamin, Gregory Hodge, Michael M McchesneyAbstract:Maternal Antibody prevents the use of live, attenuated measles vaccine (LAV) before 6–9 months of age, but vaccinated 6-month-old infants can mount a T cell response. An infant macaque model was used to study the immune response to LAV in the newborn in the presence or absence of Maternal Antibody. Four newborn monkeys without detectable Maternal Antibody and 9 newborns with passive measles Antibody were vaccinated with LAV. Only the infants without passive Antibody seroconverted after vaccination and 3 of 4 of these infants also developed measles-specific interferon γ+ T cells. The monkeys were challenged with wild-type measles virus at 5 months of age, and 7 of 9 infants vaccinated in the presence of passive Antibody had systemic infection and skin rash, while 3 of the 4 infants vaccinated in the absence of passive Antibody were protected from viremia and rash. This suggests that the newborn can respond to LAV but that Maternal Antibody suppresses the priming of both humoral and cellular immunity at birth.
-
evaluation of recombinant vaccinia virus measles vaccines in infant rhesus macaques with preexisting measles Antibody
Virology, 2000Co-Authors: Yongde Zhu, William J. Bellini, Paul A Rota, Linda S Wyatt, Azaibi Tamin, Shmuel Rozenblatt, Nicholas W Lerche, Bernard Moss, Michael M McchesneyAbstract:Immunization of newborn infants with standard measles vaccines is not effective because of the presence of Maternal Antibody. In this study, newborn rhesus macaques were immunized with recombinant vaccinia viruses expressing measles virus hemagglutinin (H) and fusion (F) proteins, using the replication-competent WR strain of vaccinia virus or the replication-defective MVA strain. The infants were boosted at 2 months and then challenged intranasally with measles virus at 5 months of age. Some of the newborn monkeys received measles immune globulin (MIG) prior to the first immunization, and these infants were compared to additional infants that had Maternal measles-neutralizing Antibody. In the absence of measles Antibody, vaccination with either vector induced neutralizing Antibody, cytotoxic T cell (CTL) responses to measles virus and protection from systemic measles infection and skin rash. The infants vaccinated with the MVA vector developed lower measles-neutralizing Antibody titers than those vaccinated with the WR vector, and they sustained a transient measles viremia upon challenge. Either Maternal Antibody or passively transferred MIG blocked the humoral response to vaccination with both WR and MVA, and the frequency of positive CTL responses was reduced. Despite this inhibition of vaccine-induced immunity, there was a reduction in peak viral loads and skin rash after measles virus challenge in many of the infants with preexisting measles Antibody. Therefore, vaccination using recombinant vectors such as poxviruses may be able to prevent the severe disease that often accompanies measles in infants.
Mary Premenkolanier - One of the best experts on this subject based on the ideXlab platform.
-
Maternal Antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth
Virology, 2006Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Azaibi Tamin, Gregory Hodge, Michael M McchesneyAbstract:Maternal Antibody prevents the use of live, attenuated measles vaccine (LAV) before 6–9 months of age, but vaccinated 6-month-old infants can mount a T cell response. An infant macaque model was used to study the immune response to LAV in the newborn in the presence or absence of Maternal Antibody. Four newborn monkeys without detectable Maternal Antibody and 9 newborns with passive measles Antibody were vaccinated with LAV. Only the infants without passive Antibody seroconverted after vaccination and 3 of 4 of these infants also developed measles-specific interferon γ+ T cells. The monkeys were challenged with wild-type measles virus at 5 months of age, and 7 of 9 infants vaccinated in the presence of passive Antibody had systemic infection and skin rash, while 3 of the 4 infants vaccinated in the absence of passive Antibody were protected from viremia and rash. This suggests that the newborn can respond to LAV but that Maternal Antibody suppresses the priming of both humoral and cellular immunity at birth.
-
protection against challenge with measles virus mv in infant macaques by an mv dna vaccine administered in the presence of neutralizing Antibody
The Journal of Infectious Diseases, 2004Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Gary Rhodes, Michael M McchesneyAbstract:Measles virus (MV) infection is the major cause of vaccine-preventable death in infants and children worldwide. It is difficult to achieve immunity to MV infection by use of vaccines in infants during the first 6-9 months of life because of the presence of Maternal Antibody. Morbidity and mortality due to MV infection would decrease substantially if a vaccine administered at birth could prime immunity in the presence of Maternal Antibody. We demonstrate here that an MV DNA vaccine administered to infant macaques in the presence of Maternal Antibody primes MV-specific T cell responses but not de novo neutralizing Antibody. This vaccine protected 80% of the infant macaques from skin rash and MV-induced immunosuppression. A molecular interleukin-2 adjuvant was required for protection with this vaccine. This macaque model shows that infants can be vaccinated against MV in the presence of Maternal Antibody. These results suggest that it is possible to develop an MV DNA vaccine that could protect infants in developing countries during the first months of life.
-
dna vaccination of infants in the presence of Maternal Antibody a measles model in the primate
Virology, 2003Co-Authors: Mary Premenkolanier, William J. Bellini, Paul A Rota, Nicholas W Lerche, Gary Rhodes, David Verhoeven, Dan H Barouch, Norman L Letvin, Michael M McchesneyAbstract:To eradicate measles in developing nations a vaccine capable of being administered at birth may be necessary. We immunized newborn rhesus macaques with naked DNA encoding the measles virus hemagglutinin, fusion and nucleoprotein genes. Prior to vaccination we passively transferred measles immunoglobulin to mimic Maternal Antibody. In the presence or absence of measles immunoglobulin, 23 of 25 infant macaques had detectable cell mediated immunity and 16 had protective levels of neutralizing Antibody. The co-administration of an IL-2/IgG plasmid augmented the vaccine, increasing cell mediated immunity in all infants and increasing the Antibody response in infants vaccinated without immunoglobulin. We show for the first time that DNA vaccination can protect a newborn primate from the high-level viremia that correlates with severe measles, even in the presence of Maternal Antibody. Further, the addition of a molecular IL-2 adjuvant augments this DNA vaccine.